Unaudited Financial Results for the Quarter ended 30 June 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 05 Aug 2026, 01:50 PM IST · BSE ID: cfc88c51-7272-49b9-9e70-c06bea93be77
View Original BSE Filing (PDF)
💡
In Simple Terms
Shilpa Medicare released its latest quarterly financial results, announced a director appointment, and confirmed a foreign investment.
🤖 AI Summary
- Board approved unaudited Q1 FY27 standalone net profit of Rs. 6,492 lakhs and consolidated net profit of Rs. 10,088 lakhs.
- Mr. Sharath Reddy Kalakota appointed as Whole-time Director, subject to member's approval at the AGM.
- Strategic equity partnership up to EUR 7 million by Shilpa Biocare in Gate2Brain confirmed.
- 39th Annual General Meeting scheduled for September 11, 2026.
- Record date for FY 2025-26 final dividend is Friday, September 4, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
18,904 Rs. In lakhs
102.26%
Standalone Net profit (Q1 FY27)
6,492 Rs. In lakhs
246.98%
Consolidated Revenue from operations (Q1 FY27)
46,578 Rs. In lakhs
44.91%
Consolidated Net profit (Q1 FY27)
10,088 Rs. In lakhs
115.19%
Investment in Gate2Brain
EUR 7 million
🏢 How This Affects the Company
The strategic equity partnership with Gate2Brain, aggregating up to EUR 7 million, indicates investment in R&D or expansion into new therapeutic areas.
Standalone revenue from operations increased to Rs. 18,904 lakhs, and consolidated revenue from operations increased to Rs. 46,578 lakhs for Q1 FY27.
The appointment of Mr. Sharath Reddy Kalakota as Whole-time Director changes the company's executive leadership structure, pending shareholder approval.
The investment in Gate2Brain involves a strategic partnership which introduces specific market and operational risks associated with foreign equity participation.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are advised to review the Notice of the 39th AGM scheduled for September 11, 2026, and to ensure shares are held by September 4, 2026, to be eligible for the final dividend for FY 2025-26.
👤
Who Is Affected
Shareholders on record as of Friday, September 4, 2026, will be eligible for the final dividend for FY 2025-26, if declared at the 39th AGM, and for e-voting and participation in the AGM.
🔍
Management Signal
Management is progressing with financial reporting, board appointments, strategic investments, and adherence to shareholder engagement timelines.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of 39th AGM on September 11, 2026, including dividend declaration.
Details of the strategic equity partnership with Gate2Brain by Shilpa Biocare.
Shareholder approval for Mr. Sharath Reddy Kalakota's appointment as Whole-time Director.
MEDIUM RISK
The strategic investment in Gate2Brain is significant, with potential for both returns and associated foreign investment risks.
💡 Investor Takeaway
Shilpa Medicare reported Q1 FY27 consolidated revenue from operations of Rs. 46,578 lakhs, up from Rs. 32,147 lakhs YoY. Consolidated net profit reached Rs. 10,088 lakhs, increasing from Rs. 4,688 lakhs in the prior year period. A strategic investment up to EUR 7 million in Gate2Brain was also announced.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Net Profit for Q1 FY27 increased to Rs. 6,492 lakhs from Rs. 1,871 lakhs in Q1 FY26.
- Consolidated Net Profit for Q1 FY27 rose to Rs. 10,088 lakhs from Rs. 4,688 lakhs in Q1 FY26.
⚠️ Concerns
- The tax expense showed a negative figure of Rs. (1,386) lakhs on a standalone basis for Q1 FY27, indicating a deferred tax asset or credit.
- The tax expense on a consolidated basis also showed a negative figure of Rs. (283) lakhs for Q1 FY27.
📅 Company Track Record
Shilpa Medicare's Board had previously announced a meeting on August 05, 2026, to approve the Q1 FY27 financial results. This filing confirms the approval of those results and other key decisions.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Shilpa Medicare's consolidated net profit for Q1 FY27?
Shilpa Medicare reported a consolidated net profit of Rs. 10,088 lakhs for the quarter ended June 30, 2026, an increase from Rs. 4,688 lakhs in the previous year's corresponding quarter.
What was Shilpa Medicare's consolidated revenue from operations in Q1 FY27?
The consolidated revenue from operations for Shilpa Medicare in Q1 FY27 was Rs. 46,578 lakhs, compared to Rs. 32,147 lakhs in Q1 FY26.
What is the strategic investment announced by Shilpa Medicare?
Shilpa Biocare Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, intends to make a strategic equity partnership investment aggregating up to EUR 7 million in Gate2Brain.
When is Shilpa Medicare's 39th Annual General Meeting?
The 39th Annual General Meeting of Shilpa Medicare Limited is scheduled to be held on Friday, September 11, 2026, at 11:00 AM through video conferencing.
What is the record date for Shilpa Medicare's final dividend for FY 2025-26?
The record date for determining shareholders entitled to the final dividend for FY 2025-26, if declared, is Friday, September 4, 2026.
Questions based on this BSE filing only. For information purposes.